Ipsen to show off strides made in renal, liver and lung cancers at ASCO

24 May 2019

French drugmaker Ipsen (Euronext: IPN) is to present new data on three of its drugs at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting – namely Cabometyx (cabozantinib), Onivyde (irinotecan) and Somatuline/Somatuline Depot (lanreotide autogel).

The Cabometyx data will include results from the Phase III CELESTIAL trial on the association of adverse events with efficacy outcomes in patients with advanced hepatocellular carcinoma.

In the same disease, among patients who have not received previous system anticancer therapy, there will also be an overview of the Phase III COSMIC-312 study of the Ipsen drug in combination with Roche’s (ROG: SIX) Tecentriq (atezolizumab), in a comparison with Bayer’s (BAYN: DE) Nexavar (sorafenib).

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK